Abstract
Analogous to the successful introduction of biologic agents to treat rheumatoid arthritis, it was widely envisaged that similar successful studies would follow in systemic lupus erythematosus (SLE), as much was known about the etiopathogenesis of the disease and appropriate agents to block the key cells and molecules were available. The reality, however, has been different. The failure of rituximab, a monoclonal antibody that induces B-cell depletion, to meet its primary and secondary end points in trials of nonrenal SLE (EXPLORER) and renal (LUNAR) lupus nephritis has been disappointing given the success reported in many open-label studies. Concluding that B-cell-depletion therapy is not effective in SLE seems rather extreme. Further analysis of the as-yet unpublished results and their comparison with data from published studies might provide insight into whether B-cell depletion will eventually be accepted as a useful approach for the treatment of SLE.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929–939 (2008).
Hostmann, A., Jacobi, A. M., Mei, H., Hiepe, F. & Dorner, T. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 17, 1064–1069 (2008).
Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435–445 (1994).
Merrill, J. T. et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER (abstract 12). Presented at the American College of Rheumatology Annual Meeting, 2008 October, San Francisco, CA, USA.
Li, E. K. et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 48, 892–898 (2009).
Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580–2589 (2004).
Vigna-Perez, M. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 6, R83 (2006).
Gottenberg J.-E. et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64, 913–920 (2005).
Smith, K. G., Jones, R. B., Burns, S. M. & Jayne, D. R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse and re-treatment. Arthritis Rheum. 54, 2970–2982 (2006).
Gunnarson, I. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56, 1263–1272 (2007).
Sutter, J. A. et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin. Immunol. 126, 282–290 (2008).
Albert, D. et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1724–1731 (2008).
Tokunaga, M. et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. 66, 470–475 (2007).
Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell co-stimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52, 501–513 (2005).
Reynolds, J. A. et al. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18, 67–73 (2009).
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R. & Isenberg, D. A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44, 1542–1545 (2005).
Cambridge, G. et al. B-cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54, 3612–3622 (2006).
Ng, K. P. et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis. 66, 1259–1262 (2007).
Jónsdóttir, T. et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis. 67, 330–334 (2008).
Iannou, Y. et al. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titers. Ann. Rheum. Dis. 67, 425–426 (2008).
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R. & Isenberg, D. A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673–2677 (2002).
Tamimoto, Y. et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 47, 821–827 (2008).
Ng, K. P. et al. Repeated B-cell depletion in treatment of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 65, 942–945 (2006).
Tanaka, Y. et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17, 191–197 (2007).
Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011–1016 (2008).
Lu, T. Y., Jónsdóttir, T., van Vollenhoven, R. F. & Isenberg, D. A. Prolonged B cell depletion following rituximab therapy in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1493–1494 (2008).
Anolik, J. H. et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455–459 (2003).
Sanz, I. The conundrum of B cell depletion in SLE. Nat. Rev. Rheumatol. 5, 304–305 (2009).
Vallerskog, T. et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. 122, 62–74 (2007).
Calabrese, L. H., Molloy, E. S., Huang, D. & Ransohoff, R. M. Progressive multifocal leukencephalopathy in rheumatic diseases. Arthritis Rheum. 56, 2116–2128 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
David A. Isenberg has acted as a consultant for Roche, but refused personal honoraria for this role, requesting instead that the support be given to local charity.
Rights and permissions
About this article
Cite this article
Favas, C., Isenberg, D. B-cell-depletion therapy in SLE—what are the current prospects for its acceptance?. Nat Rev Rheumatol 5, 711–716 (2009). https://doi.org/10.1038/nrrheum.2009.218
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.218
This article is cited by
-
B cells in autoimmune hepatitis: bystanders or central players?
Seminars in Immunopathology (2022)
-
Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan
Trials (2020)
-
Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
BMC Rheumatology (2019)
-
Resolution of inflammation: a new therapeutic frontier
Nature Reviews Drug Discovery (2016)
-
The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus
Clinical Rheumatology (2015)